Drug profile · INN
capmatinib
TABRECTA
capmatinib (TABRECTA) is a hepatocyte growth factor receptor inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01EX17
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — capmatinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
capmatinib (TABRECTA) is a hepatocyte growth factor receptor inhibitor.
Key facts
INN capmatinib
Brand TABRECTA
Mechanism Hepatocyte growth factor receptor inhibitor
Target Hepatocyte growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX17
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Primary target: Hepatocyte growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is capmatinib?
capmatinib (TABRECTA) is a hepatocyte growth factor receptor inhibitor.
What is the brand name for capmatinib?
TABRECTA is a marketed brand name for capmatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.